Search

Displaying results 2671 - 2680 of 10000 in total
  1. Drug

    TAK-428

    go.drugbank.com/drugs/DB05499
    Experimental

    It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors. … TAK-428 is a drug for treating diabetic neuropathy.

  2. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

  3. Drug

    Clorazepic acid

    go.drugbank.com/drugs/DB00628
    ApprovedIllicit

    In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation. … Similar to other benzodiazepines, the active metabolite of clorazepate enhances the binding of gamma-aminobutyric acid (GABA) to the GABA type A (GABA-A) receptor, which promotes channel opening and neuronal

    Products: TRANXILENE 5 MG KAPSUL, 50 ADET, TRANXILENE 10 MG KAPSUL, 50 ADET
  4. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    [A181084] Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD. … were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels.

    Products: PITAMIN 1 MG EFERVESAN TABLET, 30 ADET, PITAMIN 1 MG EFERVESAN TABLET, 90 ADET
  5. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. … It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).

  6. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. … The peptides themselves are most abundant in mucous cells of the gastric mucosa with TFF2 being detected in mucous layers over the tissue.

  7. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).

  8. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    An animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].

  9. Drug

    PXS-4728A free base

    go.drugbank.com/drugs/DB19177
    Investigational

    PXS-4728A free base is under investigation in clinical trial NCT05904717 (Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder).

  10. Drug

    Depreotide

    go.drugbank.com/drugs/DB11628
    ApprovedWithdrawn

    Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.